Bausch + Lomb, Clearside Biomedical launch Xipere in U.S.

Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (NSDQ:CLSD) today launched their Xipere product in the U.S.

Clearside Biomedical designed the Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis — a form of eye inflammation. Xipere works with Clearside’s proprietary SCS Microinjector to deliver the therapy to the back of the eye where sight-threatening disease occurs.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

FDA accepts resubmitted NDA for Xipere from Clearside Biomedical, Bausch Health

Bausch Health (NYSE:BHC) and Clearside Biomedical (NSDQ:CLSD) announced today that the FDA accepted their resubmitted new drug application for Xipere.

Clearside Biomedical designed the investigational Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for the treatment of macular edema associated with uveitis. Xipere works with Clearside’s proprietary SCS Microinjector to access the back of the eye where sight-threatening disease occurs.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0